Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 266,600 shares, a growth of 365.3% from the December 15th total of 57,300 shares. Based on an average trading volume of 5,240,000 shares, the short-interest ratio is currently 0.1 days. Approximately 7.6% of the company’s shares are short sold.

Hedge Funds Weigh In On Onconetix

An institutional investor recently raised its position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Onconetix, Inc. (NASDAQ:ONCO) by 83.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 562,691 shares of the company’s stock after buying an additional 256,612 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 76.04% of Onconetix worth $2,926,000 at the end of the most recent quarter. Institutional investors own 23.89% of the company’s stock.

Onconetix Trading Up 27.5 %

ONCO traded up $0.14 during trading on Monday, hitting $0.65. The company’s stock had a trading volume of 8,528,678 shares, compared to its average volume of 8,374,555. Onconetix has a twelve month low of $0.32 and a twelve month high of $21.40. The firm’s 50 day moving average price is $0.88 and its 200-day moving average price is $3.80.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.